Sacubitril/Valsartan
Treatment for Heart Failure
Typical Dosage: 49/51 mg BID up to 97/103 mg BID
Effectiveness
87%
Safety Score
65%
Clinical Trials
132
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
49/51 mg BID up to 97/103 mg BID
Time to Effect
1-3 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
21(Treat 21 patients to see 1 additional successful outcome)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,800
Monitoring:$850
Side Effect Mgmt:$250
Total Annual:$8,900
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$22,250
Comparison vs Enalapril
Cost Difference
+$7,700/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Sacubitril/Valsartan Outcomes
for Heart Failure
Efficacy Outcomes
Overall Effectiveness
+87%
Response Rate
+40%
Common Side Effects
Hypotension
+16%
Hyperkalemia
+11%
Renal impairment
+10%
Cough
+9%
Angioedema
+0.5%
Sources:
Active Clinical Trials
2 active trials recruiting for Sacubitril/Valsartan in Heart Failure
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
NCT05194111RECRUITINGPHASE1, PHASE2
53 participants
INTERVENTIONAL
Richmond, United States
Started: Aug 11, 2022
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
NCT05168787ENROLLING BY INVITATION
352 participants
OBSERVATIONAL
Dallas, United States
Started: Aug 13, 2020
Completed Clinical Trials
12 completed trials for Sacubitril/Valsartan in Heart Failure
Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India
NCT04735354COMPLETED
268 participants
OBSERVATIONAL
Mumbai, India
Started: Oct 27, 2020
The Bio-Clinical Effects of the (Sacubitril-Valsartan) Combination on Patients With Chronic Heart Failure
NCT04688294COMPLETEDPHASE4
60 participants
INTERVENTIONAL
Cairo, Egypt
Started: Jan 1, 2020
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
NCT03785405COMPLETEDPHASE3
216 participants
INTERVENTIONAL
Loma Linda, United States +78 more
Started: May 2, 2019
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
NCT06149104COMPLETEDPHASE3
8 participants
INTERVENTIONAL
Ōbu, Japan +5 more
Started: Dec 4, 2023
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
NCT02957409COMPLETED
1.01K participants
OBSERVATIONAL
Calgary, Canada +31 more
Started: May 20, 2016
Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure
NCT04434170COMPLETED
112 participants
OBSERVATIONAL
Milan, Italy
Started: Oct 15, 2018
Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.
NCT02887183COMPLETEDPHASE4
794 participants
INTERVENTIONAL
Birmingham, United States +76 more
Started: Oct 25, 2016
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
NCT03552575COMPLETEDPHASE3
93 participants
INTERVENTIONAL
Glasgow, United Kingdom +1 more
Started: Jul 1, 2018
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
NCT05613140COMPLETED
9.23K participants
OBSERVATIONAL
East Hanover, United States
Started: Aug 2, 2021
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
NCT03387163COMPLETED
402 participants
OBSERVATIONAL
New York, United States
Started: Feb 9, 2018
Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction
NCT05387967COMPLETEDPHASE4
121 participants
INTERVENTIONAL
Karachi, Pakistan
Started: Jan 1, 2021
Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.
NCT05448872COMPLETED
924 participants
OBSERVATIONAL
Trieste, Italy
Started: Nov 23, 2020
Showing 20 of 132 total trials